Device Trial Radar · NCT07948330
rTMS for Incontinence After Prostate Treatment
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
23
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- The Methodist Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- Male only, from 22 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, randomized clinical trial aims to evaluate the safety, tolerability, acceptability, and procedural feasibility of targeting the pSMA using non-invasive repetitive transcranial magnetic stimulation (rTMS) in adult males with IPT, alongside a cohort of continent controls. A total of 23 participants will be enrolled (targeting 10 evaluable IPT subjects and 10 continent controls). Participants undergo baseline fMRI using a natural bladder filling protocol, and a randomized, single-session neuronavigated rTMS protocol with concurrent pelvic floor electromyography (EMG) and functional Magnetic Resonance Imaging (fMRI) to evaluate physiological and neurofunctional changes. Safety and adverse events are monitored closely through a 1-month virtual follow-up visit. Findings from this study will establish foundational evidence for cortical modulation of pelvic floor control in IPT. Additionally, these results will guide the design of a future larger, clinical trial to optimize rTMS parameters and integrate brain neuromodulation into post-prostate treatment rehabilitation strategies.
Conditions
- Urinary Incontinence
- Prostate Treatment
- Incontinence After Prostate Treatment
Interventions
Magstim - rTMS systemDevice
The Magstim Rapid2 system is a magnetic stimulation system capable of selectively inducing, modulating, or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS. Utilizing the StimGuide navigation system, the investigators will accurately target the pelvic supplementary motor area (pSMA). The Magstim Rapid2 system is used in this study to deliver either high-frequency (excitatory) or low-frequency (inhibitory) rTMS to assess physiological and neurofunctional effects on continence control in men with incontinence after prostate treatment (IPT).
Baseline Imaging and QuestionnairesOther
Non-interventional control consistent of questionnaires and baseline brain functional MRI (fMRI) with no rTMS stimulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recruitment and Retention RateTime frame: From enrollment through the 1-month follow-up visit (approximately 2 to 3 months total per participant)
- Acceptability of InterventionTime frame: Immediately after the single rTMS treatment session (Visit 4 : 3 weeks +/- 2 weeks after enrollment)
- Adverse EventsTime frame: From informed consent through the 1-month virtual follow-up visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Houston Methodist Hospital
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.